CD137 binding fibronectin type III domains

Patent metadata

Field	Value
Publication number	US-12258385-B2
Application number	US-202217732420-A
Country	US
Kind code	B2
Filing date	Apr 28, 2022
Priority date	Dec 14, 2016
Publication date	Mar 25, 2025
Grant date	Mar 25, 2025

Abstract

FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

First claim

What is claimed:

1. A method of detecting CD137-expressing cancer cells in a tumor tissue, comprising:
conjugating an isolated protein comprising an amino acid sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, and 224 to a detectable label of to form a conjugate;
administering the conjugate to a subject; and
visualizing the CD137-expressing cancer cells to which the conjugate is bound.

2. The method of claim 1 , wherein the detectable label is selected from a radioactive isotope, a magnetic bead, a metallic bead, a colloidal particle, a fluorescent dye, an electron-dense reagent, an enzyme, a biotin, a digoxigenin, a hapten, a luminescent molecule, a chemiluminescent molecule, a fluorochrome, a fluorophore, a fluorescent quenching agent, a colored molecule, a cintillant, an avidin, a streptavidin, a protein A, a protein G, an antibody, an antibody fragment, a polyhistidine, a Ni2+, a flag tag, a myc tag, a heavy metal, an alkaline phosphatase, a peroxidase, a luciferase, an electron donor, an electron acceptor, an acridinium ester, or a colorimetric substrate.

3. The method of claim 1 , wherein the detectable label is auristatin, monomethyl auristatin phenylalanine, dolostatin, a chemotherapeutic agent, a drug, a growth inhibitory agent, or a toxin.

4. The method of claim 1 , wherein the detectable label is conjugated to the protein by a linker.

5. The method of claim 1 , wherein the detectable label is complexed with a chelating agent.

6. The method of claim 1 , wherein the conjugate further comprises a methionine at the N-terminus of the isolated protein.

7. The method of claim 1 , wherein the isolated protein is coupled to a half-life extending moiety.

8. The method of claim 7 , wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG), albumin, an albumin variant, or at least a portion of an Fc region of an immunoglobulin.

9. The method of claim 1 , wherein the isolated protein is further conjugated to a cytotoxic agent.

Assignees

• Janssen Biotech Inc

Inventors

• Diem Michael
• Hawkins Rebecca
• Jacobs Steven
• Sepulveda Manuel

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title

• A61K38/39

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title

• C07K2319/40

  containing a tag for immunodetection, or an epitope for immunisation · CPC title

• C07K2319/31

  fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title